Clinical Trial Update: Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC [Phase 4]

View source ↗

Summary

Phase 4 study assessing the safety of durvalumab in Indian adults with unresectable non-small cell lung cancer. The study has completed and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Non-small Cell Lung Cancer (NSCLC) | Phase 4 | Status: COMPLETED | Results posted: 2024-11-08